Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 278, Issue 5 22-5, 2000, Pages

  Bargout, Raed ^a   Jankov, Aleksandar ^b   Dincer, Erhan ^b   Wang, Rongqi ^b   Komodromos, Themis ^b   Ibarra Sunga, Olivia ^a,c   Filippatos, Gerasimos ^c   Uhal, Bruce D ^b,d  

^a Jr Hospital of Cook County   (United States)

^b MICHAEL REESE HOSPITAL   (United States)

^c EVANGELISMOS HOSPITAL   (Greece)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Captopril; Desethylamiodarone; Type II pneumocyte

Indexed keywords

AMIODARONE; CAPTOPRIL; SARALASIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL TYPE 2; LUNG ALVEOLUS EPITHELIUM; LUNG TOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0034074089     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.2000.278.5.l1039     Document Type: Article

References (45)

1. Akoun GM, Gauthier-Rahman S, Milleron BJ, Perrot JY, and Mayard CM. Amiodarone-induced hypersensitivity pneumonitis: evidence of an immunological cell-mediated mechanism. Chest 85: 133-135, 1984.
2. Bardales RH, Xie SS, Schaefer RF, and Hsu S. Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am J Pathol 149: 845-852, 1996.
3. Camus P and Jeannin L. Speculation on the mechanism for amiodarone-induced pneumonitis. Radiology 150: 279-280, 1984.
4. Canada A, Lesko T, Haffajee C, Johnson B, and Asdourian G. Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. Drug Intell Clin Pharm 17: 100-104, 1983.
5. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, Dyduszynski A, Maciejewicz J, Zaleska T, Lazarczyk-Kedzia E, Motyka J, Paczkowska B, Sczaniecka O, and Yusuf S. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled pilot study. J Am Coll Cardiol 20: 1056-1062, 1992.
6. Colgan T, Simon GT, Kay JM, Pugsly SO, and Eydt J. Amiodarone pulmonary toxicity. Ultrastruct Pathol 6: 199-204, 1984.
7. Crystal RG, Ferrans VJ, and Basset F. Biologic basis of pulmonary fibrosis. In: The Lung: Scientific Foundations, edited by Crystal RG and West JB. New York: Raven, 1991, chapt. 7.8.1, p. 2031-2046.
8. Deas O, Dunmont B, Mollereau D, Hirsch B, and Senik A. Thiol mediated inhibition of FAS and CD2 apoptotic signaling in activated human peripheral T-cells. Int Immunol 9: 117-125, 1997.
9. Devereux TR, Hook GER, and Fouts JR. Foreign compound metabolism by isolated cell from rabbit lung. Drug Metab Dispos 7: 70-75, 1979.
10. Dovac H, Nul O, Grancelli H, Derrone S, Bortman G, and Guriel R. Randomized trial of low-dose amiodarone in congestive heart failure. Lancet 344: 493-498, 1994.
11. Gross SA, Bandyopadhyay S, Klanning JE, and Somani P. Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture. Proc Soc Exp Biol Med 190: 163-170, 1989.
12. Hagimoto N, Kuwano K, Miyazaki H, Kunitake R, Fujita M, Kawasaki M, Kanika Y, and Hara N. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of FAS antigen. Am J Respir Cell Mol Biol 17: 272-278, 1997.
13. Herre JM, Saure MJ, and Malone P. Long term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13: 442-449, 1989.
14. Jackson F and Longmore WJ. Amiodarone effect on cultured rat type II pneumocytes (Abstract). Am Rev Respir Dis 135: A508, 1988.
15. Janse M, Malik M, Camm A, Julian O, Frongin G, and Schwartz P. Identification of post-acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. Eur Heart J 19: 85-95, 1998.
16. Karpel JP, Mitsuda S, and Norin AJ. Natural killer cell activity in a rat model of amiodarone induced interstitial lung disease. Chest 99: 230-234, 1991.
17. Kauffman SL. Cell proliferation in the mammalian lung. Int Rev Exp Pathol 22: 131-191, 1980.
18. Kennedy TP, Gordon GB, Paky A, McShane A, Adkinson NF, Peters SP, Friday K, Jackman W, Sciuto AM, and Gutner GH. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol 12: 23-36, 1988.
19. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, and Hara N. p21 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 154: 477-483, 1996.
20. Jones KG, Holland JF, Foureman GL, and Fouts JR. Xenobiotic metabolism in Clara cells and alveolar type II cells isolated from lungs of rats treated with beta-naphthoflavone. J Pharmacol Exp Ther 225: 316-319, 1983.
21. Marchlinski JL, Gansler TS, Waxyman HL, and Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 97: 939-945, 1982.
22. Martin WJ II and Howard DM. Amiodarone-induced lung toxicity. In vitro evidence for the direct toxicity of the drug. Am J Pathol 120: 344-350, 1985.
23. Martin WJ II and Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (part 1). Chest 93: 1067-1075, 1988.
24. Martin WJ II and Standing JE. Amiodarone pulmonary toxicity: biochemical evidence for a cellular phospholipidosis in the bronchoalveolar lavage of human subjects. J Pharmacol Exp Ther 224: 774-779, 1988.
25. Mundle S, Gregory S, Preisler H, and Raza A. Enzymatic programming of apoptotic cell death. Pathobiology 64: 161-170, 1996.
26. Myers JL, Kennedy JI, and Plump VJ. Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 18: 349-356, 1987.
27. Ogle CL and Reasor MJ. Response of alveolar macrophage to amiodarone and desethylamiodarone in vitro. Toxicology 62: 227-238, 1990.
28. Pfisterer M, Kiowski W, Burckhardt D, Follath F, and Burkhart F. Beneficial effects of amiodarone on cardiac mortality in patients with asymptomatic complex ventricular arrhythmias after acute myocardial infarction and preserved but not impaired left ventricular function. Am J Cardiol 69: 1399-1402, 1992.
29. Pitcher WD. Amiodarone-induced pulmonary toxicity. Am J Med Sci 303: 206-212, 1992.
30. Powis G, Olsen R, and Standing JE. Amiodarone-mediated increase in intracellular free calcium associated with cellular injury to human pulmonary artery endothelial cells. Toxicol Appl Pharmacol 103: 156-164, 1990.
31. Rabovsky J, Sapola NA, Judy D, and Castranova V. Ethoxyresorufin deethylase activity in rat alveolar type II cells (Abstract). Fed Proc 45: A637, 1986.
32. Reasor MJ and Kacew S. An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc Soc Exp Biol Med 212: 297-304, 1996.
33. Reasor MJ, Ogle CL, Walker EL, and Kacew S. Amiodarone induced phospholipidosis in rat alveolar macrophage. Am Rev Respir Dis 137: 510-518, 1988.
34. Singh SN, Fisher SG, Deedwania PC, Rohatgi P, Singh BN, and Fletcher RD. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 30: 514-517, 1997.
35. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling C, and Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 333: 77-82, 1995.
36. Uhal BD. Cell cycle kinetics in alveolar epithelium. Am J Physiol Lung Cell Mol Physiol 272: L1031-L1045, 1997.
37. Uhal BD, Flowers KM, and Rannels DE. Type II pneumocyte proliferation in vitro: problems and future directions. Am J Physiol Heart Circ Physiol Suppl (Oct) 261: 110-117, 1991.
38. Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Papp M, Flynn K, and Filippatos G. Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol Lung Cell Mol Physiol 275: L1013-L1017, 1998.
39. Uhal BD, Joshi I, Hughes WF, Ramos C, Pardo A, and Selman M. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am J Physiol Lung Cell Mol Physiol 275: L1192-L1199, 1998.
40. Uhal BD, Joshi I, True A, Mundle S, Raza A, Pardo A, and Selman M. Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol 269: L819-L828, 1995.
41. Vereckei A, Blazovics A, Gyorgy I, Feher E, Toth M, Szenasi G, Zsinka A, Foldiak G, and Feher J. The role of free radicals in the pathogenesis of amiodarone toxicity. J Cardiovasc Electrophysiol 4: 161-177, 1993.
42. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, and Uhal BD. Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol Lung Cell Mol Physiol 277: L1245-L1250, 1999.
43. Wang R, Zagariya A, Ibarra-Sunga O, Gidea C, Ang E, Deshmukh S, Chaudhary G, Baraboutis J, Filippatos G, and Uhal BD. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 276: L885-L889, 1999.
44. Wilson BD and Lippman ML. Pulmonary accumulation of amiodarone and N-desethylamiodarone. Relationship to the development of pulmonary toxicity. Am Rev Respir Dis 141: 1553-1558, 1990.
45. Witschi H. Responses of the lung to toxic injury. Environ Health Perspect 85: 5-13, 1990.